Herantis Pharma Plc: Change in the number of shares and voting rights
Herantis Pharma Plc
Company release 22 March 2019 at 10:00 am
Herantis Pharma Plc (”Herantis” or the ”Company”) announced a directed share issue of 1,111,982 new shares (the ”Issue Shares”) at a price of EUR 5.20 per share in a company release published on 12 March 2019 at 17:00 pm Finnish time.
The Issue Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office. The aggregate number of shares in the Company and the number of votes conferred by the shares is 6,030,287. Each share confers one vote.
The Issue Shares are new Herantis shares that are equivalent to the existing share class of Herantis. The ISIN code of the shares if FI4000087861.
Trading in the Issue Shares on the First North-list is expected to commence on 25 March 2019.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.